SG11201501451SA - Amine salt and crystals thereof - Google Patents

Amine salt and crystals thereof

Info

Publication number
SG11201501451SA
SG11201501451SA SG11201501451SA SG11201501451SA SG11201501451SA SG 11201501451S A SG11201501451S A SG 11201501451SA SG 11201501451S A SG11201501451S A SG 11201501451SA SG 11201501451S A SG11201501451S A SG 11201501451SA SG 11201501451S A SG11201501451S A SG 11201501451SA
Authority
SG
Singapore
Prior art keywords
crystals
amine salt
amine
salt
Prior art date
Application number
SG11201501451SA
Inventor
Kousuke Tani
Akihiro Kinoshita
Keisuke Hanada
Yoshiyuki Aratani
Takahiro Nekado
Atsushi Shimabukuro
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of SG11201501451SA publication Critical patent/SG11201501451SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
SG11201501451SA 2012-08-31 2013-08-30 Amine salt and crystals thereof SG11201501451SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012191080 2012-08-31
PCT/JP2013/073442 WO2014034902A1 (en) 2012-08-31 2013-08-30 Amine salt and crystals thereof

Publications (1)

Publication Number Publication Date
SG11201501451SA true SG11201501451SA (en) 2015-04-29

Family

ID=50183705

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501451SA SG11201501451SA (en) 2012-08-31 2013-08-30 Amine salt and crystals thereof

Country Status (24)

Country Link
US (1) US9643940B2 (en)
EP (1) EP2891651B1 (en)
JP (1) JP6131956B2 (en)
KR (1) KR102119619B1 (en)
CN (1) CN104603117B (en)
AU (1) AU2013309872B2 (en)
BR (1) BR112015004459B1 (en)
CA (1) CA2882732C (en)
DK (1) DK2891651T3 (en)
ES (1) ES2623788T3 (en)
HK (1) HK1210168A1 (en)
HU (1) HUE032816T2 (en)
IL (1) IL237432B (en)
MX (1) MX344385B (en)
MY (1) MY177737A (en)
NZ (1) NZ705340A (en)
PH (1) PH12015500389A1 (en)
PL (1) PL2891651T3 (en)
PT (1) PT2891651T (en)
RU (1) RU2658823C2 (en)
SG (1) SG11201501451SA (en)
TW (1) TWI597274B (en)
WO (1) WO2014034902A1 (en)
ZA (1) ZA201501374B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001817A2 (en) * 2019-08-04 2022-03-29 Yeda Res & Dev Methods for the preparation of fluensulfone

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (en) 1970-06-10 1975-02-04
JPS5231404B1 (en) 1971-04-28 1977-08-15
FR2204408A1 (en) 1972-10-27 1974-05-24 Wirth Pierre Phenylbutazone salts - sol in water and well tolerated
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
JPS60197667A (en) 1984-03-19 1985-10-07 Ono Pharmaceut Co Ltd Intermediate of 6-keto-prostaglandin-mimic compound and its preparation
PT1008588E (en) 1997-02-10 2003-09-30 Ono Pharmaceutical Co 11,15-O-DIAKLQUIL-PROSTAGLANDIN DERIVATIVES AND PRODUCTION PROCESS OF THE SAME AND PHARMACY WHICH CONTAIN THEM AS ACTIVE INGREDIENT
JPH11130678A (en) 1997-08-27 1999-05-18 Kaken Pharmaceut Co Ltd Agent for improving nervous disorder caused by bringing pressure on nerve
MXPA04000757A (en) 2001-07-23 2004-07-08 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4.
JP4547912B2 (en) 2002-03-05 2010-09-22 小野薬品工業株式会社 8-Azaprostaglandin derivative compound and drug containing the compound as an active ingredient
AU2002345285A1 (en) 2002-07-11 2004-02-02 Nokia Corporation Method and device for automatically changing a digital content on a mobile device according to sensor data
WO2004065365A1 (en) 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
WO2004089411A1 (en) 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. Remedy for spinal canal stenosis
EP1707208A4 (en) 2003-12-05 2010-03-17 Ono Pharmaceutical Co Blood flow promoters for cauda equina tissues
JPWO2005061492A1 (en) 2003-12-22 2007-07-12 小野薬品工業株式会社 Nitrogen-containing heterocyclic compounds and drugs containing them as active ingredients
JP4888775B2 (en) 2004-08-10 2012-02-29 小野薬品工業株式会社 Preventive and / or therapeutic agent for lower urinary tract disease comprising EP4 agonist
WO2006043655A1 (en) 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
WO2006129788A1 (en) 2005-06-03 2006-12-07 Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves
WO2009148163A1 (en) 2008-06-06 2009-12-10 小野薬品工業株式会社 Agent for contracting bladder detrusor muscle and relaxing urethral sphincter muscle
BRPI1013152B1 (en) 2009-06-10 2019-06-18 Ono Pharmaceutical Co., Ltd. COMPOSITION, PHARMACEUTICAL COMPOSITION AND MEDICATION THAT HAS ACTIVITY OF MUSCULAR DISTRESSING CONTRACT AND RELAXING MUSCULAR ACTIVITY OF URETHIC ESFINCTERES

Also Published As

Publication number Publication date
DK2891651T3 (en) 2017-06-06
CN104603117A (en) 2015-05-06
IL237432A0 (en) 2015-04-30
CA2882732C (en) 2021-03-30
EP2891651A4 (en) 2016-01-27
TWI597274B (en) 2017-09-01
IL237432B (en) 2019-05-30
HK1210168A1 (en) 2016-04-15
ES2623788T3 (en) 2017-07-12
PT2891651T (en) 2017-05-08
JPWO2014034902A1 (en) 2016-08-08
WO2014034902A1 (en) 2014-03-06
RU2015111568A (en) 2016-10-20
CA2882732A1 (en) 2014-03-06
RU2658823C2 (en) 2018-06-25
PH12015500389B1 (en) 2015-04-27
HUE032816T2 (en) 2017-11-28
ZA201501374B (en) 2016-03-30
US9643940B2 (en) 2017-05-09
US20150218114A1 (en) 2015-08-06
KR102119619B1 (en) 2020-06-05
MX2015002209A (en) 2015-05-08
BR112015004459A2 (en) 2017-07-04
MX344385B (en) 2016-12-14
CN104603117B (en) 2018-03-23
TW201414722A (en) 2014-04-16
KR20150047500A (en) 2015-05-04
AU2013309872A1 (en) 2015-03-19
AU2013309872B2 (en) 2017-09-14
PL2891651T3 (en) 2017-08-31
EP2891651B1 (en) 2017-03-08
BR112015004459B1 (en) 2020-06-30
EP2891651A1 (en) 2015-07-08
NZ705340A (en) 2018-06-29
MY177737A (en) 2020-09-23
PH12015500389A1 (en) 2015-04-27
JP6131956B2 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
IL273276A (en) Salt crystals
IL230940B (en) Noribogaine salt ansolvates
IL231265A0 (en) Amido compounds as rorɣtmodulators and uses thereof
EP2915804A4 (en) Novel amine derivative or salt thereof
HK1201521A1 (en) Heterocyclic compounds and methods for their use
HK1201533A1 (en) Heterocyclic compounds and methods for their use
HK1201531A1 (en) Heterocyclic compounds and methods for their use
EP2886546A4 (en) Heterocyclic compound and use thereof
HK1207643A1 (en) Amides of 2-amino-4-arylthiazole compounds and their salts 2--4-
PL2840907T3 (en) Salt substitute
EP2938607A4 (en) Salts and crystal forms
EP2935227A4 (en) Diazole amides
EP2902391A4 (en) Novel amine compound and use thereof
HK1215571A1 (en) Cobicostat dichlohydrate salt
EP2842937A4 (en) Amine compound and use thereof for medical purposes
EP2813508A4 (en) Heterocyclic compound and use thereof
HK1210168A1 (en) Amine salt and crystals thereof
GB201220447D0 (en) Releasable fastener
GB201219293D0 (en) Pyroelectric crystals